Capricor Stock Jumps as FDA Moves Forward with Rare Disease Treatment Review

Capricor Therapeutics shares rise 2% after FDA requests clinical trial data for deramiocel, a potential treatment for Duchenne muscular dystrophy, without requiring new studies.